Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK1 | Q13546 | 4/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.31 |
| ▸ | BACE1 | P56817 | 1/20 | 0.31 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.30 |
| ▸ | SMYD2 | Q9NRG4 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26694476 | 1.00 | RIPK1 (0.37) | RIPK1LMNAMEN1KMT2AAGTR2 | |
| SCHEMBL23043370 | 1.00 | RIPK1 (0.37) | RIPK1LMNAMEN1KMT2AAGTR2 | |
| SCHEMBL30065094 | 0.91 | RIPK1 (0.36) | RIPK1LMNAMEN1KMT2ABACE1 | |
| SCHEMBL22554958 | 0.91 | RIPK1 (0.36) | RIPK1LMNAMEN1KMT2ABACE1 | |
| SCHEMBL29889630 | 0.89 | KMT2A (0.36) | RIPK1KMT2AALDH1A1SMN1; SMN2 | |
| SCHEMBL29889644 | 0.88 | GPR119 (0.40) | LMNAMEN1KMT2AGPR119ALDH1A1 | |
| SCHEMBL22555052 | 0.88 | GPR119 (0.40) | LMNAMEN1KMT2AGPR119ALDH1A1 | |
| SCHEMBL22555283 | 0.86 | RIPK1 (0.33) | RIPK1 | |
| SCHEMBL30065579 | 0.86 | RIPK1 (0.33) | RIPK1 | |
| SCHEMBL26694854 | 0.86 | MEN1 (0.35) | RIPK1MEN1KMT2ABACE1CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4322945-A2 | KRAS G12C INHIBITORS | Mirati Therapeutics, Inc. (US) | 2024-02-21 | — | — | EP | disclosed |
| US-11548888-B2 | KRas G12C inhibitors | Mirati Therapeutics, Inc. (US) | 2023-01-10 | — | — | US | disclosed |
| EP-4087573-A1 | KRAS G12C INHIBITORS | Mirati Therapeutics, Inc. (US) | 2022-11-16 | — | — | EP | disclosed |
| US-20200331911-A1 | KRAS G12C INHIBITORS | Mirati Therapeutics, Inc. | 2020-10-22 | — | — | US | disclosed |
| US-8680092-B2 | Nitrogenous heterocyclic compound and medicinal use thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2014-03-25 | — | — | US | disclosed |
| US-20090233908-A1 | NITROGENOUS HETEROCYCLIC COMPOUND AND MEDICINAL USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2009-09-17 | — | — | US | disclosed |
| EP-1852432-A1 | NITROGENOUS HETEROCYCLIC COMPOUND AND MEDICINAL USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2007-11-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090233908-A1 | NITROGENOUS HETEROCYCLIC COMPOUND AND MEDICINAL USE THEREOF | CXCR4, CXCR1, CXCL12 | RIPK1 1223/4885LMNA 4534/4885MEN1 2268/4885 |
| US-11548888-B2 | KRas G12C inhibitors | KRAS, NRAS, HRAS | RIPK1 1634/4885LMNA 2991/4885MEN1 348/4885 |
| US-20200331911-A1 | KRAS G12C INHIBITORS | KRAS, NRAS, HRAS | RIPK1 1634/4885LMNA 2991/4885MEN1 348/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.